|Description||AZD-3147 is an extremely potent and selective dual inhibitor of mTORC1 and mTORC2. It exhibits >300-fold selectivity for mTOR over PI 3-kinase isoforms. It has physicochemical and pharmacokinetic properties suitable for development as a potential clinical candidate.|
|Solubility||Soluble to 100 mM in DMSO and to 100 mM in 1eq. HCl|
|Application||AZD-3147 has physicochemical and pharmacokinetic properties suitable for development as a potential clinical candidate.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Boiling Point||696.7±65.0 °C | Condition: Press: 760 Torr|
|Density||1.45±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
CZ415 is a highly selective potent mTOR inhibitor with little activity on other lipid and protein kinases with efficacy in a collagen induced arthritis model an...
Ku-0063794 inhibits both mTORC1 and mTORC2 with an IC50 of approximately 10 nM, but does not suppress the activity of 76 other protein kinases or seven lipid ki...
NSC781406 demonstrates potent PI3K inhibition (PI3Kα IC50=2.0 nM) and is a highly potent mTOR inhibitor, with reasonable liver microsome stability.
Torin1 inhibits phosphorylation of mTORC1 and mTORC2 substrates in cells at concentrations of 2 and 10 nM, respectively.
CC-115, a DNA-PK and mTOR inhibitor, has been found to have probable anticarcinoma effect. IC50:13 nM and 21 nM for DNA-PK and mTOR respectively.
PP242 is a novel potent and selective mTOR inhibitor with an IC50 of 8 nM. PP242 also shows residual (micromolar) activity against panel of tyrosine kinases. Bu...
WYE-125132, also known as WYE-132, is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor. WYE-132 inhibited mTORC1 and mTORC2 in diverse canc...
AZD-8055 is an inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor AZD8055 inhibits the serine/t...
GDC-0349 is a small molecule anticaner drug candidate, being developed by Genentech. As of July 2012, Genentech has filed phase I trial of GDC-0349 for evaluati...
ABTL-0812 is an orally bioavailable, lipid analogue and inhibitor of raptor-mammalian target of rapamycin (mTOR), rictor-mTOR and dihydrofolate reductase with p...
SC-III3 is a scopoletin derivative and has been found to induce the autophagy of hepatoma HepG2 cells so that could be significant in anticancer studies.
GDC-0084, a PI3K inhibitor, has been found to have probable antineoplastic effect and could pass blood-brain barrier with favourable penetration. It was just li...
Dactolisib, also known as BEZ235, is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. BEZ235 speci...
MLN0128, also known as INK128, is a TORC1/2 inhibitor, is also an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR co...
Rapamycin is a mTOR inhibitor immunosuppressant and kinase inhibitor with both antifungal and antineoplastic properties. It selectively inhibits the transcripti...
GSK1059615 is a dual inhibitor of PI3Kα/β/δ/γ (reversible) and mTOR with IC50 of 0.4 nM/0.6 nM/2 nM/5 nM and 12 nM, respectively.
Omipalisib, also known as GSK2126458, is asmall-molecule pyridylsulfonamide inhibitor of phosphatidylinositol 3-kinase (PI3K) with potential antineoplastic acti...
mTOR kinase inhibitor OSI-027 is an orally bioavailable mammalian target of rapamycin (mTOR) kinase inhibitor with potential antineoplastic activity. mTOR kinas...
NVP-BBD130 is a potent and selective dual PI3K/mTOR inhibitor. It can suppress the growth and proliferation of melanoma primary tumors and metastasis via inhibi...
CC-223, a mTOR kinase inhibitor, has been found to be effective in inducing the apoptosis and reducing the proliferation of tumor cells. It is still under Phase...